Meet with Selexis Scientific and Business Leaders at Upcoming Industry Conferences

Press Release

January 29, 2020

Meet with Selexis Scientific and Business Leaders at Upcoming Industry Conferences

Geneva, Switzerland, January 29, 2020Selexis SA, a JSR Life Sciences Company, today announced its planned participation at several industry conferences during the first quarter of 2020. Following are several opportunities to meet with the company’s leadership to learn more about its best-in-class, modular cell line development technologies and highly specialized solutions.

Selexis Lunch and Learn
29 January 2020, MassBio, 300 Technology Square, 8th Floor/Collaboration Room, Cambridge, Mass.
Selexis Chief Scientific Officer Pierre-Alain Girod, PhD is presenting “A rapid and high-throughput CHO expression platform for stable production of biotherapeutics” from 11:30 a.m. – 1:00 p.m. ET.
For more information and registration, please visit the Eventbrite page

BioProcess International US West 2020
9 – 12 March 2020, Santa Clara Convention Center, Santa Clara, California
For more information, please visit: https://informaconnect.com/bpi-west/cell-line-development-engineering

BIO Asia International Conference
10 – 11 March 2020, Grand Hyatt Roppongi, Tokyo, Japan
For more information, please visit: https://www.bio.org/events/bio-asia-international-conference

CPhI Japan
16 – 18 March 2020, Big Sight Exhibition Center, Tokyo, Japan
For more information, please visit: https://www.cphi.com/japan/

BIO-Europe Spring
23 – 25 March 2020, Porte De Versailles, Hall 7, Paris, France
Schedule a partnering meeting at https://informaconnect.com/bioeurope-spring/partnering/

About Selexis SA

Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 125 drug products in clinical development and the manufacture of six commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at https://selexis.com/about/business-development/.

###

 

FOR MORE INFORMATION

– Web              www.selexis.com
– LinkedIn      
www.linkedin.com/company/selexis-sa
– Twitter         
www.twitter.com/SelexisSA
– Facebook    
www.facebook.com/SelexisSA

  

Media Inquiries for Selexis

Mike Beyer
Sam Brown Inc.
+1 312-961-2502
mikebeyer@sambrown.com

 

Company Inquiries for Selexis

Robert Meister
Head, Corporate Communications
+1 602-953-1716
robert.meister@selexis.com